Management

New drug fights flu as well as Tamiflu does: Study

Researchers delivered a double dose of good news today in the fight against flu — successful tests of what could become the first new flu medicine in a decade, and the strongest evidence yet that such drugs save lives, not just shorten illness. - IIM-A guides schools, academia to fight swine flu - Stop calling it "Swine Flu", says US agriculture secretary - CCMB to set up BSL-3 facility to test swine flu - WHO warns of winter surge of Swine Flu in South East Asia - Swine flu will expose global health inequality: WHO - Japan has flu treatment drugs for 50 million people: govt A single intravenous dose of the experimental drug, peramivir, cleared up flu symptoms as well as five days of Tamiflu pills did, a large study in Asia found. An IV treatment is badly needed because many sick people can"t swallow pills and because illness hinders the body"s ability to absorb oral medicines. Several other studies showed the value of treatment with Tamiflu. In one study of hundreds of people stricken with bird flu around the world, half of those given Tamiflu survived, while nearly 90 per cent of those not given flu medicines died. Other research showed Tamiflu improved survival from regular seasonal flu, too. "There has been an accumulation of evidence over time that the antiviral drugs can save lives," and the new studies confirm that hope, said Nancy Cox, flu chief at the US Centres for Disease Control and Prevention. Results were reported today at an American Society for Microbiology conference in California. It is the first big meeting of infectious disease specialists since the new H1N1 swine flu emerged in April.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

News of the day
SocGen 3rd quarter net doubles
Societe Generale SA, France’s second-largest bank by market value, said third-quarter earnings doubled as its investment-banking unit returned to profit.
Popular Articles

F&O Outlook: More correction possible in coming days
The Nifty ignored all bullish indicators and closed below 5,000 on profit-booking and weak global cues. The close of 4,953 is marginally above the 61.8 per cent retracement level of 4,940. Hence, if it falls below this, it can retreat to 4,860. Also, the Nifty has gained over 10 per cent since the last week’s low of 4,538 and so more correction is possible in the coming days.

Renuka Sugars acquires Brazil firm for Rs 1,112 cr
It is the first overseas acquisition by an Indian sugar company.